New DPDP Rules: Indian Healthcare Faces ₹250 Crore Penalty Risk

LAWCOURT
Whalesbook Logo
AuthorIshaan Verma|Published at:
New DPDP Rules: Indian Healthcare Faces ₹250 Crore Penalty Risk

India’s Digital Personal Data Protection (DPDP) Act is reshaping how hospitals and diagnostic labs manage patient records. With potential penalties of up to ₹250 crore for compliance failures, healthcare providers must now overhaul their data storage, consent management, and emergency access protocols to avoid regulatory action.

The implementation of the Digital Personal Data Protection (DPDP) Act is setting a new compliance standard for India’s healthcare sector. As the rules come into force, hospitals, clinics, and diagnostic centers are facing the reality of higher accountability for patient data. One of the most significant concerns for these entities is the potential penalty of up to ₹250 crore for failing to protect patient information or failing to notify the relevant authorities during a data breach.

Navigating Emergency Access Rules

One of the critical operational aspects for hospitals is handling "break-glass" scenarios. In medical emergencies, such as treating an unconscious patient, hospitals are allowed to access personal health information without waiting for traditional, explicit consent. However, this flexibility comes with strict disclosure requirements. Healthcare providers are still required to maintain full accountability, which means they must inform patients or their guardians after such access has occurred or if a data breach takes place. This requires hospitals to implement robust internal systems to track every instance where private data is accessed under emergency provisions.

The Classification Challenge

A major point of discussion within the sector is the DPDP Act’s approach to data classification. Unlike previous discussions that sought a specific category for "sensitive personal data," the current framework applies general protections across the board. Some health policy experts have noted that a distinct category for health information could have allowed for stricter, more tailored protections—such as mandatory data-protection impact assessments or specific bans on using health data for employment or insurance decisions without explicit consent. Without this specific classification, healthcare providers must apply high-level safety standards to all patient information to manage their regulatory risk effectively.

Operational Complexities for Medical Tourism

For India’s growing medical tourism industry, the Act introduces new layers of complexity. With the industry projected to reach a size of $16.21 billion by 2030, the regular movement of patient records between domestic hospitals and international insurers is a significant business activity. While the law permits cross-border transfers, it also grants the government power to restrict transfers to specific countries. As of September 2026, no countries have been officially notified as restricted, but the evolving regulatory landscape means hospitals must now map their data flows carefully to ensure that every transfer complies with both Indian standards and international requirements.

Compliance Costs and Investor Monitoring

Beyond the operational changes, the financial impact will be a key factor for investors to monitor. Many hospitals and diagnostic chains will likely need to spend more on data security infrastructure, consent management software, and legal compliance teams to manage the fragmented data flows between doctors, insurers, and labs. The burden is particularly higher when handling children's health records, which require verifiable parental consent. For investors, the focus will remain on how efficiently these companies integrate these compliance systems without slowing down patient services or hurting profit margins. The Data Protection Board of India will oversee enforcement, and the timeline for full implementation will determine how quickly these costs hit the balance sheets of healthcare companies.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.